WallStSmart
DSGN

Design Therapeutics Inc

NASDAQ: DSGN · HEALTHCARE · BIOTECHNOLOGY

$15.79
-1.02% today

Updated 2026-06-05

Market cap
$745.11M
P/E ratio
P/S ratio
29,402.82x
EPS (TTM)
$-1.20
Dividend yield
52W range
$3 – $17
Volume
0.8M

Design Therapeutics Inc (DSGN) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item2019202020212022202320242025
Total assets$90000.00$36.52M$390.56M$341.14M$289.64M$252.09M$226.20M
Cash & equivalents$77000.00$2.38M$298.57M$26.50M$21.20M$22.56M$16.86M
Current assets$90000.00$36.23M$385.44M$335.12M$284.58M$248.04M$223.78M
Total liabilities$3.73M$47.83M$8.43M$13.83M$11.96M$10.00M$13.70M
Current liabilities$3.73M$2.33M$5.28M$10.78M$9.62M$8.46M$13.05M
Long-term debt
Shareholder equity$-3.64M$-11.31M$382.13M$327.31M$277.69M$242.10M$212.50M
Retained earnings$-3.64M$-11.92M$-47.46M$-110.76M$-177.63M$-227.21M$-297.01M
Accounts receivable$10000.00$110000.00$1.11M$1.43M$1.26M$1.68M
Inventory$107000.00$1.25M$-1.11M
Goodwill

Frequently asked questions

What is Design Therapeutics Inc's revenue?

Design Therapeutics Inc's trailing twelve-month revenue is $33000.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does DSGN generate?

DSGN produced $-54.55M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is DSGN's balance sheet healthy?

DSGN holds $16.86M in cash and equivalents against — in long-term debt, on $212.50M of shareholder equity. That debt is best read against the cash flow the business throws off each year.